Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3189.00    105.00 (3.40%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.44b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Acquisition

29 Jul 2013 07:00

RNS Number : 2528K
Croda International PLC
29 July 2013
 



29 July 2013

 

CRODA INTERNATIONAL PLC

 

Acquisition in China increases emerging market presence and strengthens Performance Technologies business

 

Croda International Plc ("Croda" or "the Group") announces that it has received Chinese regulatory approval to acquire a 65% equity interest in Sichuan Sipo Chemical Co. Ltd ("Sipo"), a non-listed natural speciality chemicals manufacturer based in Mianyang City, Sichuan Province, China. Completion of the transaction is subject to customary closing conditions which are expected to be fulfilled within the next few weeks.

 

The majority stake will be acquired from Sichuan Forever Holding Co. Ltd and certain individual shareholders for a total consideration of £38.2m*, including £8.0m* of debt, subject to working capital, net cash and fixed asset adjustments. Sichuan Forever Holding Co. Ltd will continue as the minority shareholder retaining a 35% equity interest in Sipo.

 

Sipo was established in 1993 and has approximately 300 employees. Sipo makes speciality derivatives from natural raw materials and its products include primary amides, novel fatty acids and speciality esters. In 2012 the business reported a turnover of £28.0m and EBITDA of £3.1m. A state of the art, well invested production facility, custom built in 2011, will provide additional capacity from the outset and increase Croda's proximity to customers in the region, strengthening its existing operations across China and the Group's overall position in Asia. Sipo will also consolidate Croda's global leadership in fatty acid amides and add new technology that will enable the Group to expand its portfolio across a number of its core markets.

 

Apart from a small number of by-products, all of Sipo's products will be sold through the Croda global sales network. Croda's initial focus is to grow sales from its Performance Technologies business to the Polymer Additives and Lubricants sectors, with further opportunities in new markets expected to follow in due course.

 

Steve Foots, Chief Executive of Croda, commented:

 

"This is a significant step forward in our strategy to increase Croda's presence in fast growing and emerging markets. Sipo's manufacturing capabilities together with our marketing expertise and sales force infrastructure are an exciting combination. We will have a stronger platform in niche markets and renewable technologies which will allow us to develop our customer base and drive sales growth in Asia. Our broader footprint in China will also enable us to be more responsive to customer needs in this important region."

 

For further information please contact:

 

Steve Foots, Group Chief Executive

Tel: 01405 860 551

Sean Christie, Group Finance Director

Charles Armitstead / Rosie Oddy, Pendomer Communications

Tel: 020 3603 5224

 

*purchase consideration of RMB361.6m and debt of RMB75.6m at an estimated exchange rate of RMB9.45/£.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQRFMMTMBATBMJ
Date   Source Headline
11th Jun 20262:58 pmRNSDirector/PDMR Shareholding
11th Jun 20269:15 amRNSDirector Declaration
1st Jun 20261:46 pmRNSDirector/PDMR Shareholding
29th May 20264:06 pmRNSDirector/PDMR Shareholding
29th May 20263:10 pmRNSDirector/PDMR Shareholding
29th May 20261:53 pmRNSDirector/PDMR Shareholding
29th May 20261:52 pmRNSDirector/PDMR Shareholding
29th May 20261:45 pmRNSDirector/PDMR Shareholding
15th May 20269:23 amRNSDirector/PDMR Shareholding
12th May 202612:10 pmRNSDirector/PDMR Shareholding
6th May 20261:21 pmRNSDirector/PDMR Shareholding
23rd Apr 202611:20 amRNSResult of AGM
22nd Apr 20267:00 amRNSFirst quarter 2026 sales in line with expectations
13th Apr 20261:41 pmRNSDirector/PDMR Shareholding
31st Mar 202611:48 amRNSHolding(s) in Company
26th Mar 20264:34 pmRNSDirector/PDMR Shareholding
18th Mar 20263:31 pmRNSDirector/PDMR Shareholding
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20263:27 pmRNSDirector/PDMR Shareholding
18th Mar 20263:25 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:20 pmRNSDirector/PDMR Shareholding
16th Mar 20261:36 pmRNSAnnual Financial Report
16th Mar 20261:36 pmRNSAnnual Financial Report
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
6th Mar 20261:32 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:13 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNSResults for the year ended 31 December 2025
11th Feb 20262:59 pmRNSDirector/PDMR Shareholding
13th Jan 20262:47 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSDirector Declaration
11th Dec 202511:30 amRNSDirector/PDMR Shareholding
11th Nov 202511:19 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSThird quarter 2025 sales update
14th Oct 20251:58 pmRNSDirector/PDMR Shareholding
8th Oct 20254:26 pmRNSDirector/PDMR Shareholding
1st Oct 20253:45 pmRNSDirector/PDMR Shareholding
18th Sep 20253:49 pmRNSHolding(s) in Company
12th Sep 202510:11 amRNSDirector/PDMR Shareholding
11th Sep 20253:54 pmRNSDirector/PDMR Shareholding
29th Aug 20253:58 pmRNSHolding(s) in Company
29th Aug 202511:03 amRNSHolding(s) in Company
27th Aug 20251:58 pmRNSHolding(s) in Company
22nd Aug 20254:24 pmRNSDirector/PDMR Shareholding
22nd Aug 202511:55 amRNSDirector/PDMR Shareholding
14th Aug 20259:10 amRNSDirector/PDMR Shareholding
12th Aug 202511:42 amRNSDirector/PDMR Shareholding
7th Aug 20259:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.